SAT-3247 for muscle weakness in facioscapulohumeral muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests a new medicine called SAT-3247 to see if it can safely improve muscle strength in people with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes muscle weakness, especially in the face, shoulders, and legs. Participating may help you and future patients by finding a treatment that could slow or reduce muscle loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of FSHD (type 1 or 2) through genetic testing
- You must have weakness in your arms (at least a score of 2 on the Brooke scale)
- You must have weakness in your lower legs (ankle dorsiflexion) and still be able to walk
- If you take any medicines, supplements, or do physical therapy, doses and routines must stay the same throughout the study
- You must not have certain health conditions like kidney or liver problems, a history of seizures, or recent surgery affecting medicine absorption
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new medicine, SFL-0821, to see if it is safe and useful for people with FSHD. It may help if it works, but it is still experimental.
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
This study tests a new medicine called SRP-1001 to see if it can help people with a type of muscular dystrophy called FSHD1. It aims to slow down muscle weakness and improve quality of life.
This study tests an experimental medicine called Del-brax (AOC 1020) for people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to see if it can help improve muscle strength and slow the disease. You may be able to join if you have a confirmed FSHD diagnosis and can walk at least 10 meters on your own.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
Hear when a new Facioscapulohumeral Muscular Dystrophy (FSHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.